| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRSS35 |
| Uniprot No | Q8N3Z0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-413 aa |
| 活性数据 | LIDG SEMEWDFMWH LRKVPRIVSE RTFHLTSPAF EADAKMMVNT VCGIECQKEL PTPSLSELED YLSYETVFEN GTRTLTRVKV QDLVLEPTQN ITTKGVSVRR KRQVYGTDSR FSILDKRFLT NFPFSTAVKL STGCSGILIS PQHVLTAAHC VHDGKDYVKG SKKLRVGLLK MRNKSGGKKR RGSKRSRREA SGGDQREGTR EHLRERAKGG RRRKKSGRGQ RIAEGRPSFQ WTRVKNTHIP KGWARGGMGD ATLDYDYALL ELKRAHKKKY MELGISPTIK KMPGGMIHFS GFDNDRADQL VYRFCSVSDE SNDLLYQYCD AESGSTGSGV YLRLKDPDKK NWKRKIIAVY SGHQWVDVHG VQKDYNVAVR ITPLKYAQIC LWIHGNDANC AYG |
| 分子量 | 47.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PRSS35蛋白的3篇文献示例(内容为模拟概括，非真实文献)：
1. **《PRSS35 regulates angiogenesis via protease-activated receptor signaling》**
- 作者：Smith A, et al. (2020)
- 摘要：研究重组人PRSS35蛋白通过激活PAR2受体促进内皮细胞迁移和血管生成，揭示其在组织修复中的潜在应用。
2. **《Expression and functional characterization of recombinant human PRSS35 in cancer progression》**
- 作者：Lee J, et al. (2018)
- 摘要：通过昆虫细胞系统表达重组PRSS35.证实其在肿瘤微环境中通过降解细胞外基质促进癌细胞侵袭的机制。
3. **《Structural insights into the catalytic domain of PRSS35: implications for substrate specificity》**
- 作者：Chen X, et al. (2021)
- 摘要：解析重组PRSS35蛋白的晶体结构，阐明其底物结合域的关键氨基酸残基及丝氨酸蛋白酶活性调控机制。
*注：以上文献为模拟生成，实际研究中建议通过PubMed或Google Scholar检索真实文献。PRSS35(Testisin)的研究相对较少，可尝试扩展关键词如“Testisin”或“serine protease 35”。*
PRSS35. also known as human serine protease 35. is a member of the trypsin-like serine protease family characterized by a conserved catalytic triad (His, Asp, Ser) responsible for hydrolyzing peptide bonds. Encoded by the PRSS35 gene located on chromosome 16 in humans, this enzyme is synthesized as an inactive zymogen requiring proteolytic cleavage for activation. It features a conserved structural architecture, including an N-terminal propeptide domain that regulates enzymatic activity. PRSS35 is expressed in reproductive tissues (e.g., testes, placenta), lungs, and kidneys, suggesting roles in tissue-specific processes.
Functionally, PRSS35 is implicated in extracellular matrix remodeling, cellular differentiation, and immune modulation. Studies link it to reproductive development, notably in spermatogenesis and placental formation. Emerging evidence highlights its potential involvement in pathological conditions such as fibrosis, cancer progression, and inflammatory disorders, where dysregulated protease activity may alter microenvironment signaling.
Despite these insights, PRSS35's precise biological mechanisms and physiological substrates remain poorly characterized. Animal models, including Prss35-knockout mice, display reproductive abnormalities, underscoring its developmental importance. Ongoing research aims to clarify its molecular interactions, regulatory pathways, and therapeutic potential. Challenges include elucidating its dual roles in homeostasis and disease, as well as reconciling interspecies functional variations. This enzyme represents a compelling target for understanding protease-mediated cellular dynamics and developing tailored interventions.
×
